Search results for "ExAC"

showing 10 items of 1440 documents

The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever u…

2012

Abstract Background Divergent strategies have emerged for the management of severe asthma. One strategy utilises high and fixed doses of maintenance treatment, usually inhaled corticosteroid/long-acting β2-agonist (ICS/LABA), supplemented by a short-acting β2-agonist (SABA) as needed. Alternatively, budesonide/formoterol is used as both maintenance and reliever therapy. The latter is superior to fixed-dose treatment in reducing severe exacerbations while achieving similar or better asthma control in other regards. Exacerbations may be reduced by the use of budesonide/formoterol as reliever medication during periods of unstable asthma. We examined the risk of a severe exacerbation in the per…

Pulmonary and Respiratory MedicineBudesonideExacerbationAsthma in primary careSeverity of Illness Indexlaw.inventionRandomized controlled trialDouble-Blind MethodlawAdrenal Cortex HormonesRisk FactorsFormoterol FumarateAdministration InhalationmedicineBudesonide Formoterol Fumarate Drug CombinationHumansAnti-Asthmatic AgentsBudesonideAsthmalcsh:RC705-779Maintenance dosebusiness.industryResearchlcsh:Diseases of the respiratory systemmedicine.diseaseAsthmaBronchodilator AgentsDrug CombinationsTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDisease ProgressionFormoterol FumarateDrug Therapy CombinationFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugRespiratory research
researchProduct

Oxidative Stress and Respiratory System: Pharmacological and Clinical Reappraisal of N-Acetylcysteine

2014

Abstract The large surface area for gas exchange makes the respiratory system particularly susceptible to oxidative stress-mediated injury. Both endogenous and exogenous pro-oxidants (e.g. cigarette smoke) trigger activation of leukocytes and host defenses. These mechanisms interact in a ìmultilevel cycleî responsible for the control of the oxidant/antioxidant homeostasis. Several studies have demonstrated the presence of increased oxidative stress and decreased antioxidants (e.g. reduced glutathione [GSH]) in subjects with chronic obstructive pulmonary disease (COPD), but the contribution of oxidative stress to the pathophysiology of COPD is generally only minimally discussed. The aim of t…

Pulmonary and Respiratory MedicineChronic ObstructiveAntioxidantantioxidantNeutrophilsmedicine.medical_treatmentAntioxidant; Copd exacerbation; Lung function; Small airways; Acetylcysteine; Antioxidants; Bronchitis Chronic; Disease Progression; Expectorants; Forced Expiratory Volume; Hospitalization; Humans; Macrophages; Neutrophils; Pulmonary Disease Chronic Obstructive; Reactive Oxygen Species; Respiratory Physiological Phenomena; Oxidative Stress; Pulmonary and Respiratory MedicineAntioxidant; Copd exacerbation; Lung function; Small airways; Acetylcysteine; Antioxidants; Bronchitis Chronic; Disease Progression; Expectorants; Forced Expiratory Volume; Hospitalization; Humans; Macrophages; Neutrophils; Pulmonary Disease Chronic Obstructive; Reactive Oxygen Species; Respiratory Physiological Phenomena; Oxidative StressOxidative phosphorylationReviewSettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.disease_causeAntioxidantsAcetylcysteinePulmonary Diseasechemistry.chemical_compoundPulmonary Disease Chronic ObstructiveCOPD exacerbationForced Expiratory VolumemedicineHumansRespiratory systemChronicBronchitisExpectorantschemistry.chemical_classificationCOPDReactive oxygen speciessmall airwaysbusiness.industryMacrophageslung functionGlutathionemedicine.diseaseAcetylcysteineBronchitis ChronicHospitalizationOxidative StresschemistryImmunologyDisease ProgressionRespiratory Physiological PhenomenabusinessReactive Oxygen SpeciesOxidative stressmedicine.drug
researchProduct

Phenotypes contribute to treatments.

2017

Chronic obstructive pulmonary disease (COPD) represents a major health problem in Central and Eastern European (CEE) countries; however, there are no data regarding clinical phenotypes of these patients in this region. Participation in the Phenotypes of COPD in Central and Eastern Europe (POPE) study was offered to stable patients with COPD in a real-life setting. The primary aim of this study was to assess the prevalence of phenotypes according to predefined criteria. Secondary aims included analysis of differences in symptom load, comorbidities and pharmacological treatment. 3362 patients with COPD were recruited in 10 CEE countries. 63% of the population were nonexacerbators, 20.4% frequ…

Pulmonary and Respiratory MedicineChronic bronchitismedicine.medical_specialtyExacerbation1InflammationDisease03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInternal medicinemedicineHumansCOPD030212 general & internal medicineCOPDbusiness.industryOriginal Articlesmedicine.diseasePhenotypeObstructive lung diseaserespiratory tract diseasesPhenotype030228 respiratory systemImmunologymedicine.symptomAirwaybusinessThe European respiratory journal
researchProduct

Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease

2005

Current therapy for chronic obstructive pulmonary disease (COPD) fails to alter its relentless progression. This remains a significant challenge and unmet need. A recent advance is the demonstration that treatment with a fixed dose of an inhaled corticosteroid and a long-acting beta2-agonist in COPD improves lung function and quality of life, and reduces exacerbation more effectively than either drug alone. Other improvements include the introduction of tiotropium, a once-daily anticholinergic. In advanced clinical development are other once-daily bronchodilators and combinations of anticholinergic drugs and beta2-agonists. Increased understanding of the pathogenesis of COPD has led to nove…

Pulmonary and Respiratory MedicineDrugmedicine.medical_specialtyExacerbationPhosphodiesterase Inhibitorsmedicine.drug_classmedia_common.quotation_subjectAnti-Inflammatory AgentsPharmacologySystemic inflammationAntioxidantsPathogenesisPulmonary Disease Chronic ObstructiveAdministration InhalationAnticholinergicmedicineHumansProtease InhibitorsIntensive care medicineGlucocorticoidsmedia_commonCOPDInhalationbusiness.industryAntibodies MonoclonalAdrenergic beta-Agonistsmedicine.diseaseBronchodilator Agentsrespiratory tract diseasesDrug developmentQuality of LifeSmoking Cessationmedicine.symptombusinessProceedings of the American Thoracic Society
researchProduct

High Flow Nasal Therapy Use in Patients with Acute Exacerbation of COPD and Bronchiectasis: A Feasibility Study

2020

The efficacy and feasibility of high flow nasal therapy (HFNT) use in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and bronchiectasis is unknown. We performed a single-center, single-arm prospective observational study in patients with AECOPD, documented bronchiectasis, pH >= 7.35, respiratory rate (RR) >= 26 breaths/minute despite receiving maximal medical treatment and oxygen via face mask up to 10 L/m. Patients received HFNT (Airvo 2, Fisher & Paykel) at a gas flow of 50 L/min and FIO2 adjusted to maintain SpO(2) >= 92%. Dyspnea, rated by Borg scale, RR, arterial blood gases and mucus production (ranging from 1 to 3) were collected befor…

Pulmonary and Respiratory MedicineMaleAcute exacerbation of chronic obstructive pulmonary diseasemedicine.medical_specialtyExacerbationbronchiectasishumidification03 medical and health sciencesPulmonary Disease Chronic Obstructivebronchiectasi0302 clinical medicineacute respiratory failure bronchiectasis COPD High flow nasal cannula humidification mucus plug sputumRespiratory RateInternal medicineMedicineCannulaHumansCOPDIn patientAcute respiratory failure030212 general & internal medicineProspective StudiesAgedCOPDBronchiectasisacute respiratory failurebusiness.industryOxygen Inhalation TherapysputumCarbon Dioxidemedicine.diseaseSymptom Flare UpHigh flow nasal cannulaMucusDyspnea030228 respiratory systemmucus plugSputumFeasibility StudiesFemalemedicine.symptomBlood Gas AnalysisbusinessHigh flow
researchProduct

Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.

2019

Systemic/oral corticosteroids (OCS) have been used for decades in the management of acute asthma exacerbations and chronically in patients with uncontrolled severe asthma. However, while OCS are effective at treating acute exacerbations, there is only empirical evidence regarding the efficacy of OCS at reducing the rate of exacerbations. Evidence, although scarce, is suggestive of high exacerbation rates in severe asthma patients even when receiving maintenance treatment with OCS. In addition, use of OCS is associated with undesirable effects. Despite all this, physicians have continued to use OCS for managing severe asthma and acute exacerbation due to the lack of availability of effective…

Pulmonary and Respiratory MedicineMaleAllergymedicine.medical_specialtyExacerbationInjections SubcutaneousAdministration OralOmalizumabOmalizumabAntibodies Monoclonal HumanizedSeverity of Illness Indexchemistry.chemical_compoundReslizumabAdrenal Cortex HormonesInternal medicinemedicineHumansAnti-Asthmatic AgentsAsthmaBiological Productsbusiness.industryInterleukin-4 Receptor alpha SubunitImmunoglobulin Emedicine.diseaseBenralizumabReceptors Interleukin-5DupilumabAsthmachemistryAdministration IntravenousFemaleInterleukin-5businessMepolizumabmedicine.drug
researchProduct

Importance of noninvasively measured respiratory muscle overload among the causes of hospital readmission of COPD patients.

2008

To evaluate the influence of respiratory muscle overload and right cardiac overload among the possible risk factors of hospital readmission in a 1-year follow-up of a cohort of patients with moderate-to-severe COPD.A total of 112 COPD patients who were admitted consecutively to the hospital for acute exacerbation. At hospital discharge, we evaluated the conventional clinical and functional determinations in addition to the pressure-time index (PTI), which is obtained using the equation PTI = (Pawo/Pimax) x (Ti/Ttot) x 100, where Pawo represents the mean airway pressure measured at the mouth during spontaneous breathing, Pimax is the maximal inspiratory pressure, Ti is the inspiratory time, …

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyExacerbationmedicine.medical_treatmentAtrial Function RightKaplan-Meier EstimateMean airway pressureCritical Care and Intensive Care MedicinePatient ReadmissionCohort StudiesElectrocardiographyPulmonary Disease Chronic ObstructivePredictive Value of TestsInternal medicineOxygen therapymedicineRespiratory muscleHumansAgedProportional Hazards ModelsCOPDmedicine.diagnostic_testbusiness.industryRespiratory diseaseOxygen Inhalation TherapyMiddle Agedmedicine.diseasePrognosisRespiratory MusclesSurgeryRespiratory Function TestsInhalationCardiologyBreathingVentricular Function RightCardiology and Cardiovascular MedicinebusinessElectrocardiographyFollow-Up StudiesChest
researchProduct

Tracheostomy in patients with long-term mechanical ventilation: a survey.

2010

Summary Background Tracheostomy is increasingly performed in intensive care units (ICU), with many patients transferred to respiratory ICU (RICU). Indications/timing for closing tracheostomy are discussed. Aim and Method We report results of a one-year survey evaluating: 1) clinical characteristics, types of tracheostomy, complications in patients admitted to Italian RICU in 2006; 2) clinical criteria and systems for performing decannulation, and outcome of patients undergoing tracheostomy (number decannulated; number non-decannulated/non-ventilated; number non-decannulated/ventilated; dead/lost patients). Results 22/32 RICUs replied. There were 846 admissions of 719 patients (Mean age 64,3…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyPercutaneousSettore MED/09 - Medicina InternaExacerbationCritical Caremedicine.medical_treatmentRespiratory failureSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionTracheostomylawIntensive caremedicineHumansIn patientIntensive care unitMechanical ventilationbusiness.industryLong-term mechanical ventilationMiddle Agedmedicine.diseasePrognosisIntensive care unitRespiration ArtificialSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSurgeryObstructive sleep apneaTreatment OutcomeRespiratory failureItalyHealth Care SurveysTracheostomy Intensive care unit Long-term mechanical ventilation Respiratory failureFemalebusinessRespiratory InsufficiencyVentilator Weaning
researchProduct

P141 2-year follow-up of COPD patients in the non-interventional ‘real-life’ daccord study in germany

2016

Introduction Although randomised, controlled trials are important in the development of new pharmacological treatments, they provide limited information on the ‘real life’ management of chronic diseases. Here, we analysed two-year follow-up data from the prospective, non-interventional, observational DACCORD study to evaluate the frequency of exacerbations and the evolution of disease severity using GOLD 2011 categorization. Methods COPD out-patients were recruited into DACCORD following either a change or initiation of COPD maintenance medication and followed up for 2 years. Data of 3137 patients that completed the 2-year follow-up were analysed; Exacerbation data were collected from the 6…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyCOPDExacerbationbusiness.industryCopd patientsmedicine.diseaseLower riskCohortNon interventionalmedicineObservational studybusinessProgressive diseaseThorax
researchProduct

P46 Frequency of COPD exacerbations in the German DACCORD Registry

2015

Introduction In patients with COPD, exacerbations are among the most relevant safety measures. In this analysis of data from the observational DACCORD study, we report the frequency of exacerbations in a COPD population. Methods To get insights into occurrence and frequency of exacerbations, data from 4,123 patients were obtained from 349 primary and secondary care centres in Germany. To be eligible for entry into DACCORD, all patients had to have a COPD diagnosis (consistent with the German Disease Management Programme definition), and had to have a change in bronchodilator maintenance medication, prior to entry. Data collected included history and treatment of exacerbations 6 months prior…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyCOPDeducation.field_of_studyExacerbationbusiness.industrymedicine.drug_classPopulationDiseasemedicine.diseaseBronchodilatorCohortMedicineObservational studyMedical prescriptionbusinesseducationThorax
researchProduct